ReproSource

What ReproSource does

ReproSource, Inc. is a CLIA-licensed specialty reference laboratory providing fertility and reproductive health diagnostic testing services to fertility specialists, OB/GYNs, reproductive urologists, and clinical research organizations across the United States and internationally. Founded in 2008 and headquartered in Marlborough, Massachusetts, the company operates a proprietary portfolio of laboratory-developed tests (LDTs) built around multivariate biomarker algorithms rather than single-analyte assays. Core products include the Ovarian Assessment Report (OAR), an age-adjusted multivariate algorithm combining AMH, FSH, inhibin B, and estradiol into an Egg Supply Score; the Advanced Semen Report 2.0 (ASR 2.0), which combines Sperm DNA Fragmentation Assay with the proprietary Oxidative Stress Adduct (OSA) test on a single specimen; the YCMD 3.0 Y Chromosome Microdeletion panel co-developed with the Page Laboratory at MIT's Whitehead Institute; and a broader test menu spanning recurrent pregnancy loss, antiphospholipid antibodies, HLA/KIR genotyping, reproductive immunophenotyping, karyotyping, Fragile X, MTHFR, Factor V Leiden, cystic fibrosis carrier screening, and vitamin D quantification. The company also operates an @Home specimen collection service for semen analysis and ships prepaid collection kits nationally.

ReproSource sells exclusively through a B2B2C commercial insurance billing model, accepting all commercial payer plans across all 50 US states but not participating in Medicare or Medicaid. The go-to-market motion is enterprise field sales combined with an inside client services team: field reps conduct a structured five-step onboarding for new healthcare provider accounts (needs assessment, supply delivery, in-service training, ongoing support), and the company submits claims on behalf of patients through payer contracts with national carriers (Aetna, BCBS, Cigna, Humana) and state-specific plans. Technical differentiation rests on outcomes-validated algorithms calibrated against large internal research cohorts (17,120+ women for AMH, 5,354+ for AMH/FSH discordance, 774+ men for OSA), peer-reviewed publications in Fertility and Sterility, and regulatory credentials including CLIA, CAP, ISO 15189:2022, and ISO 14001:2015. ReproSource operates as a private subsidiary within the Quest Diagnostics (NYSE: DGX) ecosystem, leveraging the parent's billing infrastructure and branding systems. The leadership team identified in the input comprises CEO Benjamin Leader; no further management disclosure is available.

Name

ReproSource

Legal name

ReproSource, Inc.

Website

https://reprosource.com

Company type

Private

Founded year

2008

Operating status

Operating

Headcount range

11–50 employees

Short description

ReproSource is a CLIA-licensed specialty reference laboratory providing proprietary fertility diagnostic tests to fertility specialists, OB/GYNs, reproductive urologists, and CROs, billing through commercial insurance plans across all 50 US states. It operates as a Quest Diagnostics subsidiary.

Ownership category

akta.pro rank

Product category

Clinical Fertility Diagnostics

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Central Laboratory & Clinical Trial Testing CROs (HLAGAAAE)

akta.pro secondary industries

Proteomics & Mass Spectrometry Services (HLAGANAB), Proteomics & Biomarker Analytical Testing (HLAGADAG), Reproductive Endocrinology & Infertility (IVF/Fertility) (HLAKAJAC)

Keywords

• Fertility diagnostic testing
• Reproductive health services
• Clinical laboratory services
• Sperm DNA analysis
• Ovarian reserve testing

Headquarters

HQ city

Woburn

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Laboratory Diagnostic Testing Services: ReproSource operates as a specialized reference laboratory providing fertility diagnostic testing services. Revenue is generated through clinical laboratory testing billed to commercial insurance plans, with patients and healthcare providers as the ordering entities. The company submits claims to all commercial insurance plans and has contracts with numerous national and state-specific insurance providers across the United States.
2. Insurance Billing & Reimbursement: Direct billing to commercial insurance providers. ReproSource participates with multiple national and regional health insurance plans across all 50 states. The company does not participate with Medicare or Medicaid programs.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Core offering

ReproSource is a CLIA-licensed reference laboratory that provides specialty fertility diagnostic testing services to clinicians and clinical research organizations. Its core products are proprietary laboratory-developed tests—including the Ovarian Assessment Report (OAR), Advanced Semen Report 2.0 (ASR 2.0), YCMD 3.0 Y-chromosome microdeletion assay, and @Home semen collection—that evaluate egg supply, sperm DNA integrity, oxidative stress, recurrent pregnancy loss risk, and related reproductive parameters.

Product overview

ReproSource is a CLIA-licensed reference laboratory providing a comprehensive portfolio of fertility diagnostic tests. The company's core offerings include the Ovarian Assessment Report (OAR), a proprietary blood test combining multiple hormone markers with a multivariate algorithm to assess egg supply; the Advanced Semen Report 2.0 (ASR 2.0), combining sperm DNA fragmentation and oxidative stress testing; the @Home Collection service for convenient semen analysis; and the YCMD 3.0 Y chromosome microdeletion assay developed with MIT. Beyond these flagship products, ReproSource offers an extensive test menu organized into categories including Tests A-F (coagulation factors, antibodies, chromosomal analysis, genetic screens), Tests G-O (HLA typing, immunology panels), and Tests P-Z (reproductive panels, cytokine testing, endocrinology). The portfolio serves fertility specialists, OB/GYNs, reproductive urologists, and clinical research organizations worldwide, addressing female fertility, male fertility, and recurrent pregnancy loss diagnostics.

Differentiator

Problem solved

Functional benefit

Products and services

• Ovarian Assessment Report (OAR) A proprietary blood test that combines a woman's age with serum levels of AMH, FSH, inhibin B, and estradiol through a multivariate algorithm to produce an Egg Supply Score (1–20) calibrated directly to ovulatory egg supply. It is used by fertility specialists and OB/GYNs to assess ovarian reserve and predict stimulation response.
• Advanced Semen Report 2.0 (ASR 2.0) A proprietary panel that combines Sperm DNA Fragmentation Assay (SDFA) using acridine orange flow cytometry with the Oxidative Stress Adduct (OSA) colorimetric assay on a single specimen. It reports DNA Fragmentation Index (DFI), High DNA Sustainability (HDS), and OSA scores to evaluate male infertility and predict IUI/IVF outcomes.
• Semen Analysis with @Home Collection A comprehensive semen evaluation covering 23 parameters across semen characteristics, sperm analysis, and cells/inflammation categories, performed on specimens collected via the ReproSource @Home Collection kit that allows remote patient collection and next-day analysis.
• Y Chromosome Microdeletion Assay (YCMD 3.0) A comprehensive Y chromosome microdeletion test developed with MIT's Page Laboratory using enhanced PCR primers and additional confirmatory STSs positioned within critical spermatogenesis genes. It identifies distal and newly characterized deletions to support diagnosis of male infertility and TESE planning.
• RPL Standard Panel 1.3 A recurrent pregnancy loss panel aligned with ACOG and ASRM guidelines that evaluates endocrine, immune, and genetic risk factors commonly associated with pregnancy loss.
• APA Report 1.0 Expanded Panel An antiphospholipid antibody panel that detects auto-antibodies against phospholipid headgroups including phosphatidylethanolamine, phosphatidylserine, phosphatidic acid, phosphatidylglycerol, and phosphatidylinositol for recurrent pregnancy loss evaluation.
• APA Report 1.0 Standard Panel An ELISA-based antiphospholipid antibody panel that detects antibodies against cardiolipin, beta-2 glycoprotein 1, and APhL phospholipids, aligned with ACOG standard-of-care guidelines for pregnancy loss testing.
• Reproductive Immunophenotyping (RIP) A FACS-based lymphocyte sub-population quantification assay that measures CD3+, CD4+, CD8+, NK cells, B cells, and regulatory T cells to support immune system evaluation in reproductive health contexts.
• Chromosomal Microarray, POC, ClariSure Oligo SNP An oligo/SNP array assay of products of conception that detects genomic alterations associated with fetal miscarriage, used in conjunction with conventional cytogenetics testing.
• Chromosome Karyotyping (Parental) A chromosome analysis reporting the number and arrangement of chromosomes (46XX or 46XY) to identify abnormalities affecting fertility in both women and men.
• HLA Genotype Sequenced Panel A next-generation sequencing assay that determines HLA genotype including HLA A, B, C, DQ (alpha and beta), and DR for male or female genotypes.
• KIR Panel A PCR-based assay for Killer Immunoglobulin-like Receptors (KIR) genotyping associated with infectious diseases, pregnancy disorders, and immunopathologies.

Quantifiable outcome

• Semen with abnormal DFI results had a 98.5% chance of experiencing IUI failure, while live-birth rates with IVF+ICSI were nearly double those of IVF alone
• +3 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Two partnerships are on record, tiered core and major.

• Page Laboratory at MIT Whitehead InstitutecoreTechnology or IntegrationReproSource collaborated with Dr. David Page's laboratory at MIT's Whitehead Institute to develop the YCMD 3.0 Y Chromosome Microdeletion test. The Page Laboratory originally sequenced the Y chromosome in 1997, and this partnership enabled development of a proprietary panel with enhanced primers that can identify up to 48% more clinically significant Y chromosome deletions than standard commercial tests.
• The Jones Institute for Reproductive MedicinemajorStrategic or Co-development PartnerCollaborated with the Jones Institute for Reproductive Medicine at Eastern Virginia Medical School on multiple research studies including AMH and IVF outcomes research, ovarian reserve index validation, and egg donation cycle studies. Joint authorship on multiple peer-reviewed publications advancing fertility diagnostics.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Labcorp: One of the two largest US clinical reference labs, offering a broad menu of reproductive endocrinology, semen analysis, and genetic testing. Directly comparable to ReproSource in lab services, but with vastly broader test menu, geographic reach, and payer contracts.
• Quest Diagnostics: ReproSource's reported parent company and the other US reference lab giant. Directly comparable in CLIA reference lab services, with overlapping reproductive hormone and infertility testing within a much broader commercial menu.
• Myriad Genetics: Specialty molecular diagnostics company with reproductive and hereditary cancer testing products. Comparable as a specialty lab with proprietary assays, established commercial relationships with clinicians, and a heavy reliance on insurance reimbursement.
• Invitae (now Labcorp Genetics): Genetic testing company with a reproductive health offering (carrier screening, NIPS, PGT) serving OB/GYNs and fertility specialists. Comparable in proprietary testing, clinician-targeted GTM, and a referral-driven specimen flow.
• CooperSurgical (CooperCompanies): Major fertility and women's health company offering ART/IVF consumables, genomics, and lab services to the same fertility specialist customer base. Comparable in serving reproductive endocrinology practices with proprietary, specialist-facing offerings.

Direct peers

• Natera: Specialty reproductive and oncology genetic testing lab whose products (e.g., Empower, Vistara, Spectrum) compete in the fertility and preimplantation testing space. Comparable in serving fertility specialists and reproductive urologists with proprietary, validated diagnostics.
• BioReference Health (OPKO Health subsidiary): Specialty clinical laboratory with reproductive and women's health testing serving OB/GYNs and reproductive specialists. Comparable in clinician-channel lab services and proprietary reproductive test panels, but with a larger overall menu.

Emerging players

• GeneDx (formerly Sema4): Specialty reproductive and rare disease genetics lab, with offerings in carrier screening and reproductive health. Comparable in B2B2C specialty lab model, but broader in genetic focus than ReproSource's fertility-dominant menu.
• Ro (Ro Fertility / Modern Fertility): Direct-to-patient fertility hormone testing brand (Modern Fertility) and telehealth provider addressing ovarian reserve and hormone testing. Comparable in fertility diagnostic scope, with a contrasting D2C model rather than ReproSource's B2B2C channel.
• Genomic Prediction: Niche reproductive genetics lab focused on preimplantation genetic testing for IVF clinics. Comparable as a specialty reference lab serving fertility specialists, though narrower in scope and more research-oriented than ReproSource.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/reprosource-inc-

Compliance10 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ReproSource